Shots:
- Akari has entered into a strategic research collaboration with Whitehawk to evaluate Akari’s PH1 spliceosome-modulating payload tech in combination with Whitehawk’s TOP1i ADC platform
- As per the deal, Akari will lead the design, execution, & evaluation of the research program, which will incl. multiple preclinical workstreams assessing dual-payload compatibility & potential synergies
- Collaboration begins immediately, with interim data updates expected as the studies progress. The companies will jointly review the findings to determine whether the results support further development, as they explore the potential of dual-payload ADCs
Ref: Globenewswire | Image: Akari & Whitehawk | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
